Research
Reduced-dose maintenance: the SURMOUNT-MAINTAIN concept
Reduced-dose maintenance — lowering to a smaller dose after reaching goal weight — is a studied concept for tirzepatide (the SURMOUNT-MAINTAIN design
Reduced-dose maintenance — lowering to a smaller dose after reaching goal weight — is a studied concept for tirzepatide (the SURMOUNT-MAINTAIN design tested a reduced 5 mg dose), unlike semaglutide, which lacks an equivalent trial. It is a clinician-guided strategy, not the same as a commercial 'microdose.'
What the trials establish
SURMOUNT-4 established that stopping tirzepatide causes regain. The reduced-maintenance question — can a lower dose hold the loss? — is what the SURMOUNT-MAINTAIN design specifically set out to study for tirzepatide, testing a reduced 5 mg dose against the maximum tolerated dose.
This gives tirzepatide a modest evidence footing for reduced-dose maintenance that semaglutide does not have. But 'reduced maintenance' still means a clinician lowering a previously effective dose under monitoring — not a shopper starting at a sub-therapeutic 'microdose.'
The distinction matters for anyone reading maintenance marketing: a studied reduced-dose strategy in a trial is a different thing from a commercial microdose with no outcome data.
| Trial | Population | N | Result | Citation | Identifiers |
|---|---|---|---|---|---|
| SURMOUNT-4 | Adults with obesity after lead-in | 670 | Continued treatment maintained loss; withdrawal led to regain | Aronne LJ, et al. JAMA 2024;331(1):38-48 | NCT04660643 · PMID 38078870 · DOI |
Identifiers verified against ClinicalTrials.gov and PubMed. Machine-readable dataset: studies.json · studies.csv.
What remains unknown
Across this topic, the recurring gap is the same: the randomized evidence describes approved products at studied doses, while compounded and deliberately sub-therapeutic 'microdose' use sits outside it. This page marks that boundary rather than blurring it.
What the evidence shows
- The cited trials carry verified NCT, PMID, and DOI identifiers and studied approved products at labeled doses.
- Findings here reflect those trials' actual results and populations.
What the evidence does not show
- That a compounded or microdose version reproduces these results — it has not been studied.
- That approved-product evidence transfers automatically to compounded formulations.
Frequently asked questions
Is reduced-dose maintenance proven?
It's a studied concept for tirzepatide (reduced 5 mg design); it remains an individualized clinical decision.
Is that the same as microdosing?
No — reduced maintenance lowers an effective dose under supervision; microdosing is a commercial below-label term.
Related: evidence database · research hub. Compounded medications are not FDA approved.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.